Flatiron Health at ISPOR 2026
Philadelphia, PA
May 17-20, 2026
Booth #316
Flatiron is excited to attend and showcase our research at ISPOR 2026, validating exciting novel methodologies that will shape the future of evidence generation and health outcomes research in oncology.
Unlock critical evidence to accelerate access to cancer treatments worldwide
At Flatiron, we transform HEOR evidence for oncology's highest-stakes decisions. Our unified, global oncology engine combines the industry's highest-fidelity real-world data with expert-validated AI to turn complexity into clarity.
With multinational data assets across the US, UK, Germany, and Japan—and a decade of strategic partnerships with regulators and HTAs—we deliver tailored, gold-standard evidence that payers and regulators trust. We calibrate our approach to match your specific evidence needs, whether navigating regulatory submissions, demonstrating value to payers, or addressing international market access.
Join our experts at Booth #316 to see how we translate evidence into confident decision-making that shapes the future of oncology access and advances patient care globally.
Flatiron networking reception
Monday, May 18, 2026
7:00 - 10:00 PM ET
Join us for an evening of networking, cocktails, and hors d’oeuvres. This is a great opportunity to connect with colleagues, industry peers, and the Flatiron team.
Featured speaking session
Beyond Black Boxes: Transparent, Validated LLM Workflows for Accelerating Global HTA Submissions and Decisions
SESSION DETAILS
When: Wednesday, May 20, 10:00–11:00 AM ET
How do we ensure AI-powered tools generate reliable evidence? This session will explore validation frameworks that are customized for different uses—from extracting clinical data and physician insights to conducting network analyses and submitting evidence to regulators. Speakers will share real-world examples, including Flatiron’s VALID framework for assessing accuracy and the use of automation to speed up regulatory submissions in low- and middle-income countries. The discussion covers key challenges: keeping AI outputs transparent, maintaining clinical oversight, and communicating uncertainty. The goal: strengthen validation practices so AI can improve efficiency while preserving scientific rigor and supporting better decisions globally.
Our research
|
Read more about our accepted research at this year’s conference. |
Poster presentations
Assessing quality of a LLM-derived prostate cancer (PC) real-world dataset: an application of the validation of accuracy for LLM/ML-extracted information and data (VALID) framework
Author Affiliations: Flatiron Health
Read the research
See this research
Date: May 18
Time: 4-7 PM
Poster Session: 2
Poster Code: MSR65
Real-world treatment patterns and outcomes in patients with 2L+ advanced or progressive endometrial cancer
Author Affiliations: Genmab, Swedish Cancer Institute, Flatiron Health
Read the research
See this research
Date: May 18
Time: 4-7 PM
Poster Session: 2
Poster Code: HSD38
Customization of a large language model approach to capture PSA and imaging derived real-world progression events in prostate cancer
Author Affiliations: Flatiron Health
Read the research
See this research
Date: May 19
Time: 4-7 PM
Poster Session: 4
Poster Code: RWD123
Evaluating model performance for between-country survival transportability
Author Affiliations: Flatiron Health
Read the research
See this research
Date: May 19
Time: 4-7 PM
Poster Session: 4
Poster Code: MSR169
From real-world data (RWD) to digital twins: Building models for patient-level counterfactual prediction in oncology
Author Affiliations: Flatiron Health
Read the research
See this research
Date: May 20
Time: 9-11:30 AM
Poster Session: 5
Poster Code: MSR219
External control arm feasibility across external data sources in oncology: Methodological and regulatory considerations
Author Affiliations: Friends of Cancer Research, Pancreatic Cancer Action Network, ConcertAI, AbbVie,Amgen, Medidata, Ontada, COTA Healthcare, iOMEDICO, Genentech, Flatiron Health, Aetion/Datavant, American Society of Clinical Oncology
See this research
Date: May 20
Time: 9-11:30 AM
Poster Session: 5
Poster Code: RWD154
Real-world data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-world evidence services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your genitourinary cancer portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Looking for support in designing and executing HEOR studies with RWE?
Leverage Flatiron’s industry leading multinational oncology data assets and expertise to drive your real-world studies, including:
- Evaluating comparative- and cost-effectiveness
- Modeling long-term survival
- Examining burden of illness
- Analyzing treatment patterns
- Qualitative understanding of clinical decision-making and prescribing behavior
Reach out to learn more about how we partner to accelerate patient access to oncology therapies across the globe